Corporate General Counsel in the pharmaceutical industry for 22 years.
30 years international experience in international business law and M&A.
After 5 years in two international law firms specialized in international business law and M&A, he joins Ipsen, a pharmaceutical company with more than 30 affiliates worldwide, to accompany its international growth and rapidly, he is appointed General Counsel and Chief Compliance Officer. A few of his achievements includes Ipsen industrial implantation in China back in 1992, several M&A operations (UK, USA), 320 M€ IPO on Euronext in 2005 and prevails in all Ipsen litigations, in particular he obtains damages of 39M€ in the USA and 18M€ in France.
He is a registered attorney at the Bar of Paris and he creates his own law firm in 2013 in partnership with AVA-LAW. With a very operational and pragmatic approach, he advises French and foreign life science and information and communication companies for all their R&D industrial or commercial projects and their private equity or M&A transactions.
He holds a double Master’s in business law and international business law and is a doctor in international business law (University of Tours). He also holds an MBA for the Sorbonne University in Paris.
He is an active member of a number of French and foreign associations and professional organizations in the field of law in life sciences, information and communication technology and compliance. He regularly speaks at universities and conferences on issues related to Intellectual Property, international contracts and compliance.
A Dual experience : In house and counsel
In House : Willy joined the pharmaceutical industry in 1990 and has been corporate General Counsel for 22 years.
Counsel : Willy started his career as a legal counsel in 1985 both in Paris in London in international business law and M&A.
He is a registered attorney at the Paris bar since 2013.
Global approach: counsel and conflicts management
Willy primarily intervenes as counsel and he has the victorious experience of a number of litigations. (39M€ in USA, 18M€ in France).